TCON TRACON Pharmaceuticals Inc.

0.71
-0.02  -3%
Previous Close 0.73
Open 0.74
Price To Book 0.99
Market Cap 21228076
Shares 29,898,698
Volume 335,630
Short Ratio
Av. Daily Volume 538,279

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Enrolment to be terminated - April 12, 2019.
TRC105 + Opdivo
Non-small cell lung cancer (NSCLC)
Phase 1 data to be presented 1H 2019.
TRC253
Prostate cancer
Phase 2 data due 1H 2020.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 data December 21, 2018 did not meet primary endpoint.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 primary endpoint not met - November 19, 2018.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2020.
TRC102
Mesothelioma cancer
Phase 3 interim analysis April 12, 2019 noted trial to be terminated due to futility.
TRC105 (TAPPAS)
Angiosarcoma cancer
Phase 2 poster presented April 3, 2019 at AACR.
TRC102 and Temodar (temozolomide)
Colorectal cancer

Latest News

  1. Bad news for Apple, Tracon slides, Boeing completes test flights
  2. Tracon Pharmaceuticals shares slide 45% premarket after it ends trial of cancer treatment
  3. TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee
  4. TRACON Pharmaceuticals Announces TRC105, TRC253 and TRC102 Data Presentations at Upcoming AACR Annual Meeting
  5. How Should Investors React To TRACON Pharmaceuticals, Inc.’s (NASDAQ:TCON) CEO Pay?
  6. Edited Transcript of TCON earnings conference call or presentation 28-Feb-19 9:30pm GMT
  7. TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
  8. TRACON Pharmaceuticals, Inc. to Host Earnings Call
  9. TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019
  10. TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma
  11. Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  12. Stocks to Watch Before The Opening Bell on December 27, 2018
  13. The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede
  14. TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer
  15. TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors
  16. TRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma
  17. TRACON Pharmaceuticals and I-Mab Biopharma Reschedule Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
  18. TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
  19. TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
  20. TRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting